Literature DB >> 17712743

Epidemiology of staphylococcal resistance.

Andrew F Shorr1.   

Abstract

An understanding of the prevalence of resistant Staphylococcus aureus and the risk factors for infection with resistant isolates is essential to help clinicians choose appropriate antibiotic therapy. Selection pressure due to prior and inappropriate antibiotic use of any kind seems to be the main driving force behind the increasing rates of multidrug resistance in methicillin-resistant S. aureus (MRSA) strains. Resistance to glycopeptide antibiotics in MRSA has also emerged in recent years, along with increased use of vancomycin to treat serious infections due to MRSA. Infections due to MRSA are associated with significantly increased morbidity, mortality, length of hospital stay, and costs, compared with infections due to methicillin-susceptible S. aureus, despite adjustment for disease severity and initially appropriate antibiotic treatment. Improvements in the preparation and dissemination of antibiograms, along with adequate public reporting of MRSA trends, are needed to address the challenge of choosing appropriate initial antibiotic treatment for MRSA infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712743     DOI: 10.1086/519473

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

1.  Prevalence of methicillin resistant Staphylococcus aureus in nasal samples from preclinical second-year medical students.

Authors:  Neal R Chamberlain; Vineet K Singh
Journal:  Mo Med       Date:  2011 Sep-Oct

2.  Efficacy of Novel Antistaphylococcal Ectolysin P128 in a Rat Model of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Shankaramurthy Channabasappa; Murali Durgaiah; Ravisha Chikkamadaiah; Senthil Kumar; Amruta Joshi; Bharathi Sriram
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Increasing Multidrug Antibiotic Resistance in MRSA Infections of the Hand: A 10-Year Analysis of Risk Factors.

Authors:  Justin M Kistler; Colin M Vroome; Frederick V Ramsey; Asif M Ilyas
Journal:  Hand (N Y)       Date:  2019-03-22

4.  Hospital-Acquired Methicillin-resistant Staphylococcus aureus Bacteremia Related to Medicare Antibiotic Prescriptions: A State-Level Analysis.

Authors:  Bryce T Fukunaga; Wesley K Sumida; Deborah A Taira; James W Davis; Todd B Seto
Journal:  Hawaii J Med Public Health       Date:  2016-10

5.  Impact of a surveillance screening program on rates of methicillin-resistant Staphylococcus aureus infections with a comparison of surgical versus nonsurgical patients.

Authors:  Andrew Jennings; Monica Bennett; Tammy Fisher; Alan Cook
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-04

6.  Comparison of antibiotic resistance, virulence gene profiles, and pathogenicity of methicillin-resistant and methicillin-susceptible Staphylococcus aureus using a Caenorhabditis elegans infection model.

Authors:  Terissa Thompson; Paul D Brown
Journal:  Pathog Glob Health       Date:  2014-10-16       Impact factor: 2.894

Review 7.  MRSA Incidence and Antibiotic Trends in Urban Hand Infections: A 10-Year Longitudinal Study.

Authors:  Justin M Kistler; Joseph J Thoder; Asif M Ilyas
Journal:  Hand (N Y)       Date:  2018-01-11

8.  Short term statin treatment improves survival and differentially regulates macrophage-mediated responses to Staphylococcus aureus.

Authors:  Erin M Burns; Lisa K Smelser; Jenny E Then; Traci E Stankiewicz; Michael Kushdilian; Susan A McDowell; Heather A Bruns
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

Review 9.  MRSA virulence and spread.

Authors:  Michael Otto
Journal:  Cell Microbiol       Date:  2012-07-17       Impact factor: 3.715

10.  Infected prosthetic dialysis arteriovenous grafts: a single dialysis center study.

Authors:  Petr Bachleda; Lucie Kalinova; Petr Utikal; Milan Kolar; Kristyna Hricova; Tatana Stosova
Journal:  Surg Infect (Larchmt)       Date:  2012-12-10       Impact factor: 2.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.